An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)